For millions at risk of glaucoma, the silent thief of sight often strikes without warning. The disease, a leading cause of irreversible blindness worldwide, typically progresses undetected until permanent optic nerve damage has already occurred. Now, emerging research suggests genetic information could hold the key to earlier detection, potentially transforming how clinicians identify and manage this devastating condition before vision is lost.
Glaucoma affects more than 76 million people globally, a number projected to rise as populations age. The disease’s asymptomatic nature in its early stages means nearly half of those affected remain undiagnosed until significant vision impairment occurs. Current screening methods rely on intraocular pressure measurements and optic nerve assessments, which, while valuable, often detect damage only after it has begun. Genetic markers could enable clinicians to identify high risk individuals years before symptoms appear, shifting the paradigm from reactive treatment to proactive prevention.
Recent studies have identified multiple genetic variants associated with an increased risk of developing glaucoma. These markers are linked not only to the disease’s onset but also to its progression and response to treatment. For instance, variations in the MYOC, OPTN, and TBK1 genes have been strongly correlated with primary open angle glaucoma, the most common form of the disease. Additionally, polygenic risk scores, which aggregate the effects of numerous genetic variants, are showing promise in predicting which patients are most likely to experience rapid disease progression.
DISCUSSION (0)